Iloprost

CAS : 78919-13-8

Ref. TR-I267300

Informations sur le produit

• Nom: Iloprost
• Synonymes: Pentanoic acid, 5-[(3aS,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]-, (5E)-, Pentanoic acid, 5-[(3aS,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-ynyl]-2(1H)-pentalenylidene]-, (5E)- (9CI), (5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]pentanoic acid, (1S,2R,3R,5S)-7-[(E)-4-Carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-bicyclo[3.3.0]octane, Ciloprost, Endoprost, Ilomedin
• Marque: TRC
• Description: Stability Light and Temperature SensitiveApplications A synthetic analogue of Prostacyclin (PGI2) used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and ischemia. It acts through elevation of cAMP by binding to the prostacyclin receptor (IP receptor). Iloprost inhibits the ADP, thrombin, and collagen-induced aggregation of human platelets with an ED50 of about 13 nM. In whole animals, iloprost acts as a vasodilator, hypotensive, antidiuretic, and prolongs bleeding time.References Zamudio, T.P.: Arch. Cardiol. Mex., 77, 198 (2007); Lai, Y. et al.: Am. J. Resp. Crit. Care Med., 178, 188 (2008); Scorza, R. et al.: J. Rheutamol., 24, 1944 (1997); Melillo, E. et al.: Int. J. Microcircul. Clin. Exp., 15, 60 (1995)

Propriétés chimiques

• Masse moléculaire: 360.49
• Formule: C₂₂H₃₂O₄
• Couleur/Forme: Colourless To Light Yellow
• InChI: InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1
• Code InChI: InChIKey=OTMSDBZUPAUEDD-UHFFFAOYSA-N
• SMILES: CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O